Pembrolizumab (Keytruda®). HTA ID: 24013

Assessment Status Rapid Review Complete
HTA ID 24013
Drug Pembrolizumab
Brand Keytruda®
Indication Pembrolizumab, in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of resectable non-small cell lung carcinoma (NSCLC) at high risk of recurrence in adults.
Assessment Process
Rapid review commissioned 22/04/2024
Rapid review completed 16/05/2024
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of pembrolizumab in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment of resectable NSCLC, compared with the current standard of care.